Australian medicine is entering a generational transition, with millennials set to become the largest cohort as baby boomer and Generation X doctors retire over the next decade.
This is a challenge because trust in pharma companies is particularly low among younger clinicians.
This whitepaper draws on recent research to help pharma marketers, sales and medical teams’ future proof their engagement with the next generation of clinicians over the next five to ten years.
With most pharmaceutical companies currently embarking on the same omnichannel strategy, from a doctor’s perspective, this results in a relentless deluge of emails, webinar invites and promotional material. So, what should pharmaceutical companies and their representatives consider going forward?
Our network offers an integrated suite of advertising solutions allowing clients to reach more doctors and other medical specialists, more frequently, on more devices every day.
With many GPs no longer seeing sales representatives, pharmaceutical companies should be prepared to engage and support GPs under a digitally led model.
COVID-19 created opportunities for pharmaceutical companies to find new ways to engage with GPs. While face-to-face rep visits are likely to remain integral, it’s clear that increasingly time-poor GPs are seeking synthesised, relevant insights in a timely manner and want to drive the engagement on their terms.